SG Americas Securities LLC Has $1.33 Million Stock Holdings in Revolution Medicines, Inc. $RVMD

SG Americas Securities LLC lifted its holdings in Revolution Medicines, Inc. (NASDAQ:RVMD) by 56.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 16,723 shares of the company’s stock after buying an additional 6,009 shares during the period. SG Americas Securities LLC’s holdings in Revolution Medicines were worth $1,332,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of RVMD. Nextech Invest Ltd. boosted its position in shares of Revolution Medicines by 20.7% in the fourth quarter. Nextech Invest Ltd. now owns 7,601,087 shares of the company’s stock worth $332,472,000 after buying an additional 1,304,347 shares during the period. Millennium Management LLC boosted its position in shares of Revolution Medicines by 681.8% in the first quarter. Millennium Management LLC now owns 156,353 shares of the company’s stock worth $5,529,000 after buying an additional 136,353 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Revolution Medicines by 14.2% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 300,196 shares of the company’s stock worth $10,615,000 after buying an additional 37,345 shares during the period. Invesco Ltd. boosted its position in shares of Revolution Medicines by 19.3% in the second quarter. Invesco Ltd. now owns 227,019 shares of the company’s stock worth $8,352,000 after buying an additional 36,760 shares during the period. Finally, Jump Financial LLC boosted its position in shares of Revolution Medicines by 87.9% in the second quarter. Jump Financial LLC now owns 15,258 shares of the company’s stock worth $561,000 after buying an additional 7,137 shares during the period. Institutional investors and hedge funds own 94.34% of the company’s stock.

Insider Buying and Selling

In other Revolution Medicines news, CFO Jack Anders sold 2,753 shares of the business’s stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $99.48, for a total value of $273,868.44. Following the completion of the sale, the chief financial officer directly owned 125,512 shares of the company’s stock, valued at $12,485,933.76. The trade was a 2.15% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Xiaolin Wang sold 2,010 shares of the business’s stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $99.48, for a total transaction of $199,954.80. Following the completion of the sale, the insider directly owned 116,063 shares of the company’s stock, valued at $11,545,947.24. This represents a 1.70% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 64,592 shares of company stock valued at $6,488,732. 8.20% of the stock is owned by company insiders.

Analyst Ratings Changes

Several brokerages have recently commented on RVMD. Benchmark reaffirmed an “overweight” rating on shares of Revolution Medicines in a research report on Tuesday, February 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Revolution Medicines in a research report on Thursday, January 22nd. Wedbush reaffirmed an “outperform” rating on shares of Revolution Medicines in a research report on Friday, January 9th. Jefferies Financial Group began coverage on Revolution Medicines in a report on Monday, March 16th. They set a “buy” rating for the company. Finally, Evercore upgraded Revolution Medicines to a “strong-buy” rating in a report on Wednesday, February 25th. Five analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Revolution Medicines currently has an average rating of “Buy” and an average price target of $78.94.

Revolution Medicines Price Performance

Shares of NASDAQ:RVMD opened at $96.29 on Wednesday. The company has a current ratio of 7.14, a quick ratio of 7.14 and a debt-to-equity ratio of 0.16. Revolution Medicines, Inc. has a 1 year low of $29.98 and a 1 year high of $124.49. The business has a fifty day simple moving average of $98.18 and a 200 day simple moving average of $81.78. The firm has a market cap of $19.08 billion, a price-to-earnings ratio of -16.29 and a beta of 1.01.

Revolution Medicines (NASDAQ:RVMD) last posted its earnings results on Wednesday, February 25th. The company reported ($1.86) EPS for the quarter, missing the consensus estimate of ($1.56) by ($0.30). During the same period in the prior year, the company earned ($1.12) EPS. As a group, sell-side analysts predict that Revolution Medicines, Inc. will post -3.49 earnings per share for the current fiscal year.

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.